No content to show...
Description
CardiaMetrics – €20M Series A
The next-generation hemodynamic monitoring for heart failure
CardiaMetrics is developing SCOUT, a subcutaneous implant similar to an implantable Holter monitor. It uses AI and cardiac signals to estimate filling pressures (PCWP) automatically, every day, in patients with chronic heart failure. This replaces patient-initiated readings from a vascular sensor. Hemodynamic monitoring of this kind allows medication to be adjusted, much as blood glucose does for people with diabetes.
Our promise: “Take back control”
- Leading medical board: Prof. François Roubille, Prof. William Abraham and Prof. Michael Zile, international opinion leaders in heart failure, guide our clinical strategy. Prof. Abraham presented the first results of the ASEMC-DR study (Caen).
- US accelerator: Philippe Wanstok, former President of MicroPort CardioFlow, is our strategic advisor (positioning, market access, FDA, industry partners).
- Market: 65M patients worldwide, with roughly $60B in potential annual savings for healthcare systems.
- Traction: Pre-Series A completed, 2026 i-Lab laureate, Bpifrance and Region Normandy support, backed by Lyonbiopôle and Normandeeptech.
- Next milestone: first-in-human implantation expected in Q1 2027.
- The raise: €20M Series A (€15M dilutive + €5M non-dilutive) to fund clinical expansion and the FDA/CE pathway.
Our Documents
Our Media
SCOUT
